At the helm of Parallel Immunotherapeutics, our team is reshaping cancer therapy by leveraging innate antibody mechanisms to target and eradicate various cancers. With over a decade in executive leadership, I've established a robust portfolio of oncology drugs that are now transitioning into clinical trials, a testament to our commitment to innovation and patient care.Paratope Bio's collaboration with non-profits has been instrumental in advancing pediatric oncology research. By examining the innate antibody variations expressed at birth, we aim to uncover the susceptibilities to pediatric cancers. Our research is fueled by a passion for solving complex biological puzzles and a steadfast dedication to making a tangible difference in the lives of those affected by cancer.